SCHEMBL6035564

SCHEMBL6035564

CCOc1nn(-c2ccc(C(F)(F)F)cc2)cc1CCCOc1cccc(CC(=O)O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G4B P0C869 1/20 0.42
PPARD Q03181 13/20 0.42
PPARA Q07869 13/20 0.42
FFAR2 O15552 1/20 0.40
LTB4R Q15722 1/20 0.40
RXRA P19793 3/20 0.40
CYP2C9 P11712 2/20 0.40
RXRB P28702 2/20 0.40
RXRG P48443 2/20 0.40
NR3C1 P04150 1/20 0.40
THRA P10827 1/20 0.40
THRB P10828 1/20 0.40
PPARG P37231 1/20 0.40
ESR2 Q92731 1/20 0.40
DGAT1 O75907 1/20 0.39
MEN1 O00255 1/20 0.39
NR1I2 O75469 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
VHL P40337 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035583 0.90 PLA2G4B (0.40) PLA2G4BPPARDPPARAFFAR2LTB4R
SCHEMBL6035680 0.88 PLA2G4B (0.40) PLA2G4BPPARDPPARALTB4RRXRA
SCHEMBL6035924 0.85 SMN1; SMN2 (0.39) PLA2G4BPPARDPPARAFFAR2LTB4R
SCHEMBL6035708 0.84 PPARA (0.43) PPARDPPARAPPARGDGAT1
SCHEMBL6035734 0.84 PPARD (0.46) PPARDPPARARXRACYP2C9RXRB
SCHEMBL6143205 0.84 PPARA (0.44) PLA2G4BPPARDPPARARXRACYP2C9
SCHEMBL6034677 0.82 LTB4R (0.40) PPARDPPARALTB4RPPARG
SCHEMBL6036223 0.82 PLA2G4B (0.43) PLA2G4BPPARDPPARALTB4RPPARG
SCHEMBL6035703 0.82 DGAT1 (0.37) PPARDPPARAPPARGDGAT1
SCHEMBL6035705 0.82 PPARA (0.45) PPARDPPARAPPARGDGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 PLA2G4B 4180/4885PPARD 2488/4885PPARA 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.